Prediction of immunotherapy targets for chronic cerebral hypoperfusion by bioinformatics method.
10.7507/1001-5515.202409037
- Author:
Mei ZHAO
1
;
Yanpeng XUE
2
;
Qingqing TIAN
2
;
He YANG
2
;
Qing JIANG
2
;
Mengfan YU
2
;
Xin CHEN
2
Author Information
1. Department of Pharmacy, Sanya Central Hospital (The Third People's Hospital of Hainan Province), Sanya, Hainan 572000, P. R. China.
2. Department of Neurosurgery, First Affiliated Hospital of Harbin Medical University, Harbin 150001, P. R. China.
- Publication Type:Journal Article
- Keywords:
Bioinformatics;
Chronic cerebral hypoperfusion;
Immunotherapy
- MeSH:
Humans;
Computational Biology/methods*;
Brain Ischemia/therapy*;
Immunotherapy;
MicroRNAs/genetics*;
Signal Transduction;
Dementia, Vascular/genetics*;
Chronic Disease
- From:
Journal of Biomedical Engineering
2025;42(2):382-388
- CountryChina
- Language:Chinese
-
Abstract:
Chronic cerebral hypoperfusion (CCH) plays an important role in the occurrence and development of vascular dementia (VD). Recent studies have indicated that multiple stages of immune-inflammatory response are involved in the process of cerebral ischemia, drawing increasing attention to immune therapies for cerebral ischemia. This study aims to identify potential immune therapeutic targets for CCH using bioinformatics methods from an immunological perspective. We identified a total of 823 differentially expressed genes associated with CCH, and further screened for 9 core immune-related genes, namely RASGRP1, FGF12, SEMA7A, PAK6, EDN3, BPHL, FCGRT, HSPA1B and MLNR. Gene enrichment analysis showed that core genes were mainly involved in biological functions such as cell growth, neural projection extension, and mesenchymal stem cell migration. Biological signaling pathway analysis indicated that core genes were mainly involved in the regulation of T cell receptor, Ras and MAPK signaling pathways. Through LASSO regression, we identified RASGRP1 and BPHL as key immune-related core genes. Additionally, by integrating differential miRNAs and the miRwalk database, we identified miR-216b-5p as a key immune-related miRNA that regulates RASGRP1. In summary, the predicted miR-216b-5p/ RASGRP1 signaling pathway plays a significant role in immune regulation during CCH, which may provide new targets for immune therapy in CCH.
